Login to Your Account



Other News To Note


Tuesday, April 23, 2013
• Advaxis Inc., of Princeton, N.J., said it entered a memorandum of understanding with FusionVax Inc., of Taiwan, under which Advaxis will, subject to a definitive agreement, exclusively license its lead clinical-stage product candidate, ADXS-HPV, to FusionVax for development in Asia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription